AVE 0991 | 304462-19-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: AVE 0991
• 英文别名: 2-Thiophenesulfonamide, N-((ethylamino)carbonyl)-3-(4-((5-formyl-4-methoxy-2-phenyl-1H-imidazol-1-yl)methyl)phenyl)-5-(2-methylpropyl)-；1-ethyl-3-[3-[4-[(5-formyl-4-methoxy-2-phenylimidazol-1-yl)methyl]phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylurea
• CAS: 304462-19-9
• 化学式: C₂₉H₃₂N₄O₅S₂
• 分子量: 580.729
• InChiKey: QTOZBSNPDCWHPV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  40
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  156
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-甲基-1-噻吩-2-丙烷-1-酮 在 氯磺酸 、 氢氧化钾 、 ammonium hydroxide 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 溴 、 potassium carbonate 、 一水合肼 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 二氯甲烷 、 水 、 异丙醇 、 丙酮 、 三乙二醇 为溶剂， -5.0~160.0 ℃ 、220.0 kPa 条件下， 反应 12.0h， 生成 AVE 0991
  参考文献：
  名称：

  ¹⁴C-Labeled and Large-Scale Synthesis of the Angiotensin-(1−7)-receptor Agonist AVE 0991 by Cross-Coupling Reactions

  摘要：

  The synthesis of C-14-labeled AVE 0991 (C-14-1a) and large-scale synthesis of AVE 0991 (1a) are described. In the key step of the synthesis, the C-C coupling reaction of the imidazole (2) and thiophene (3) building blocks was studied under Suzuki and Stille reaction conditions, respectively. Suzuki reaction gave only moderate yields, whereas the best results were obtained under Stille reaction conditions with up to 64% yield.

  DOI：

  10.1021/jo034372c

文献信息

• Methods and compositions for the treatment of epidermolysis bullosa
  申请人：Constant Therapeutics LLC

  公开号：US10960045B2

  公开（公告）日：2021-03-30

  A method of treating epidermolysis bullosa comprising administering to a subject suffering from epidermolysis bullosa an angiotensin (1-7) peptide is described. In some embodiments, methods of treating a complication of epidermolysis bullosa are described including administering to a subject suffering from one or more complications of epidermolysis bullosa an angiotensin (1-7) peptide, wherein the administration results in a reduction in the intensity, severity, duration, or frequency of at least one symptom or feature of the one or more complications of epidermolysis bullosa.

  描述了一种治疗大疱性表皮松解症的方法，该方法包括向患有大疱性表皮松解症的受试者施用血管紧张素（1-7）肽。在一些实施方案中，描述了治疗大疱性表皮松解症并发症的方法，包括向患有大疱性表皮松解症的一种或多种并发症的受试者施用血管紧张素（1-7）肽，其中施用血管紧张素（1-7）肽可降低大疱性表皮松解症的一种或多种并发症的至少一种症状或特征的强度、严重程度、持续时间或频率。
• METHODS AND COMPOSITIONS FOR THE TREATMENT OF EPIDERMOLYSIS BULLOSA
  申请人：Tarix Pharmaceuticals Ltd.

  公开号：EP3373951B1

  公开（公告）日：2021-11-17
• COMPOSITIONS AND METHODS FOR TREATMENT OF PERIPHERAL VASCULAR DISEASE
  申请人：Tarix Pharmaceuticals Ltd.

  公开号：US20130210726A1

  公开（公告）日：2013-08-15

  The present invention relates to compositions and methods for the treatment of peripheral vascular disease (PVD). In particular, the invention provides compositions and methods for treatment of critical limb ischemia, and related diseases, disorders or conditions, based on the use of angiotensin-(1-7) peptides or functional equivalents, analogs or derivatives, angiotensin-(1-7) receptor agonists, ACE2 and/or ACE2 activators.
• COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETES
  申请人：TARIX PHARMACUTICALS LTD.

  公开号：US20140088002A1

  公开（公告）日：2014-03-27

  The present invention relates to compositions and methods for treatment and/or prevention of diabetes or pre-diabetes. In particular, the invention provides compositions and methods for the treatment and/or prevention of diabetes or pre-diabetes, based on the use of angiotensin-(1-7) peptides, functional equivalents thereof, and/or angiotensin (1-7) agonists.
• ANGIOTENSIN PEPTIDES IN TREATING MARFAN SYNDROME AND RELATED DISORDERS
  申请人：TARIX PHARMACEUTICALS LTD

  公开号：US20150031634A1

  公开（公告）日：2015-01-29

  The present invention provides, among other things, methods of treating Marfan Syndrome and/or a Marfan-related disorder including administering to a subject suffering from or susceptible to Marfan Syndrome and/or a Marfan-related disorder an angiotensin (1-7) peptide. In some embodiments, the angiotensin (1-7) peptide is administered at an effective dose periodically at an administration interval such that at least one symptom or feature of Marfan Syndrome and/or a Marfan-related disorder is reduced in intensity, severity, duration, or frequency or has delayed in onset.